Table 2 Clinical outcomes arising from the meta-analysis5

From: Updated cost-effectiveness analysis of supplemental glutamine for parenteral nutrition of intensive-care patients

 

Parameter a

95% CI

No. of trials (patients)

Mortality rate, RR

0.69

0.54–0.88

16 (n=1338)

Infection rate, RR

0.79

0.67–0.93

19 (n=1102)

Weighted mean reduction in length of hospital stay (days)

2.29b

3.65–0.94

20 (n=1140)

  1. Abbreviations: CI, confidence interval; No., number; RR, relative risk.
  2. aResults shown are for adequate doses of parenteral glutamine (>0.2 g/kg body weight per day).
  3. bThis absolute reduction in length of stay (in days) was also converted into a relative reduction (RR=0.91; 95% CI: 0.86–0.96), and it was subsequently applied to ICU and ward length of stay for patients receiving parenteral glutamine.
Back to article page